The oestrogen receptor (ER) has been identified in normal and neoplastic epithelia of the vulva, vagina and ovary using biochemical, immunohistochemical (IHC) and molecular techniques. Its presence has not translated into effective antineoplastic therapy for malignancies arising from these sites.